Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors

0 reviews

Mark Pegram, MD


1.00 / AMA PRA Category 1 Credit TM 1.00 / CNE Contact Hour

Program Description This webcast is intended to improve the care of patients with HR+ and HER2- metastatic breast cancer by accelerating the adoption of new guidelines and evidence-based practice change. ...

Read more about this

I'm interested in this

Share with others

Write the first review

Join now
to leave a review or read peer reviews!

Resource tags
Show all tags

Share with others

I'm interested